Douglas E. Gladstone

5.3k citations

113 papers · 2.5k indexed · h-index 28

Impact in

Hematology top 1%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
Transplantation top 2%

Papers in

Hematology 55
- Hematopoietic Stem Cell Transplantation 36
- Acute Myeloid Leukemia Research 13
Genetics 36
- Chronic Lymphocytic Leukemia Research 29

Co-authors: Richard J. Jones Ephraim J. Fuchs Lode J. Swinnen Robert A. Brodsky Richard F. Ambinder Leo Luznik Javier Bolaños‐Meade Thomas H. Brannagan
Journals: Blood (21 papers)Biology of Blood and Marrow Transplantation (17 papers)Blood Advances (7 papers)Leukemia Research (4 papers)Journal of Clinical Oncology (4 papers)
Partner nations: United States Italy Spain

In The Last Decade

Douglas E. Gladstone

111 papers receiving 2.3k citations

Peers

Countries citing papers authored by Douglas E. Gladstone

Since Specialization

Citations

This map shows the geographic impact of Douglas E. Gladstone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas E. Gladstone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas E. Gladstone more than expected).

Fields of papers citing papers by Douglas E. Gladstone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas E. Gladstone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas E. Gladstone. The network helps show where Douglas E. Gladstone may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Douglas E. Gladstone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas E. Gladstone Line = papers co-authored together Douglas E. Gladstone links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022 Blood Advances ·Ajay K. Gopal, Philippe Armand, Sattva S. Neelapu, Nancy L. Bartlett, Stephen E. Spurgeon, John Kuruvilla, Kerry J. Savage, John P. Leonard, Arnold B. Gelb, N. U. Ahmed, Roberto Mendes Franco, Sai Praneeth Bathena, Claudell Burnell, Qun Wu, Keisuke Ymamoto, Douglas E. Gladstone	2025	1
2	The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment Frontiers in Immunology ·Edina Komlódi-Pásztor, Zhenlin Zhang, Lawrence O. Johnsen, P. Suganthi, Jinqiang Mo, Marcus Messmer, Richard F. Ambinder, Douglas E. Gladstone, Pascal M. Kruttasch, Amy Goodrich, Lisa Landin, 石川県小松市立松東中学校, Christopher J. VandenBussche, Peng Huang, Matthias Holdhoff, Maximillian Rosario	2024	1
3	Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS Blood Advances ·Douglas E. Gladstone, Franco R. D’Alessio, Christopher Howard, Paul Salmon, Jason R. Mock, Kevin W. Gibbs, Darryl Abrams, Meixian Huang, Azadeh Vakili, James Herlihy, Sergio Castillo, Roland Bassett, 최은미, Simrit Parmar, Christopher R. Flowers, Siddhartha Mukherjee, David Schoenfeld, Peter F. Thall, Arthur S. Slutsky	2023	22
4	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial Journal of Hematology & Oncology ·(unknown), Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn Tore Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova‐Clarkson, Amela Ganibegovic, Priti Patel, Federico Rotolo, Emmanuel Mitry, Ira Pastan, Francis J. Giles	2021	56
5	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide Biology of Blood and Marrow Transplantation ·Amy E. DeZern, Hany Elmariah, Marianna Zahurak, Gary L. Rosner, Douglas E. Gladstone, Syed Abbas Ali, Carol Ann Huff, Lode J. Swinnen, Philip Imus, Ivan Borrello, Nina D. Wagner‐Johnston, Richard F. Ambinder, Robert A. Brodsky, Kenneth R. Cooke, Leo Luznik, Ephraim J. Fuchs, Javier Bolaños‐Meade, Richard J. Jones	2020	22
6	Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation Biology of Blood and Marrow Transplantation ·Philip Imus, Amanda L. Blackford, Maria Bettinotti, Leo Luznik, Ephraim J. Fuchs, Carol Ann Huff, Douglas E. Gladstone, Richard F. Ambinder, Ivan Borrello, Butler III, Lode J. Swinnen, Nina D. Wagner‐Johnston, Christian B. Gocke, Syed Abbas Ali, Civale Leonardo, Richard J. Jones, Amy E. DeZern	2019	56
7	White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab Journal of Neuro-Oncology ·Sorasak Jaingeawkum, Xiaobu Ye, Omar Dzaye, Nina D. Wagner‐Johnston, Lode J. Swinnen, Douglas E. Gladstone, J Liu, David Kamson, 李方伦, Stuart A. Grossman, Doris Lin, Matthias Holdhoff	2019	11
8	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia Biology of Blood and Marrow Transplantation ·Suman Paul, Hua-Ling Tsai, DeJuran Richardson, Ephraim J. Fuchs, Leo Luznik, Javier Bolaños‐Meade, Lode J. Swinnen, Satish Shanbhag, Nina D. Wagner‐Johnston, Ravi Varadhan, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone	2019	8
9	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma Biology of Blood and Marrow Transplantation ·Nilanjan Ghosh, Xiaobu Ye, Hua-Ling Tsai, Javier Bolaños‐Meade, Ephraim J. Fuchs, Leo Luznik, Lode J. Swinnen, Douglas E. Gladstone, Richard F. Ambinder, Ravi Varadhan, Satish Shanbhag, Robert A. Brodsky, Ivan Borrello, Richard J. Jones, William Matsui, Carol Ann Huff	2017	12
10	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia Clinical Cancer Research ·Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Showel, Douglas E. Gladstone, Mark J. Levis, Hua-Ling Tsai, Gary L. Rosner, Alice P. Chen, Scott H. Kaufmann, Judith E. Karp	2016	38
11	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors Biology of Blood and Marrow Transplantation ·Jennifer A. Kanakry, Christopher D. Gocke, Javier Bolaños‐Meade, Douglas E. Gladstone, Lode J. Swinnen, Amanda L. Blackford, Ephraim J. Fuchs, Carol Ann Huff, Ivan Borrello, William Matsui, Robert A. Brodsky, Gary L. Rosner, Satish Shanbhag, Leo Luznik, Richard J. Jones, Richard F. Ambinder, Yvette L. Kasamon	2015	16
12	Donor HLA-specific Abs: to BMT or not to BMT? Bone Marrow Transplantation ·Mary S. Leffell, Richard J. Jones, Douglas E. Gladstone	2015	48
13	Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis Biology of Blood and Marrow Transplantation ·Jennifer A. Kanakry, Yvette L. Kasamon, Javier Bolaños‐Meade, Ivan Borrello, Robert A. Brodsky, Ephraim J. Fuchs, Nilanjan Ghosh, Douglas E. Gladstone, Christopher D. Gocke, Carol Ann Huff, Christopher G. Kanakry, Leo Luznik, William Matsui, Patricia Lynn Scott, Lode J. Swinnen, Heather J. Symons, Richard J. Jones, Richard F. Ambinder	2013	79
14	Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab Journal for ImmunoTherapy of Cancer ·Andres Forero, Mehdi Hamadani, Thomas J. Kipps, Michelle A. Fanale, Antonio Cuneo, Jaime Pérez de Oteyza, Douglas E. Gladstone, Marc André, Naresh Bellam, Trishna Goswami, Ramy Ibrahim, Amy Schneider, Meina Liang, Steven Eck, Nairouz Elgeioushi, Ronald Herbst, Bruce D. Cheson	2013	3
15	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia Haematologica ·Yan Xiaoxin, Elizabeth Garrett‐Mayer, Elihu H. Estey, Michelle A. Rudek, Benjamin D. Smith, Judith M. Greer, Aisyah Lailana, Katherine Mackey, Kathleen Shannon Dorcy, Steven D. Gore, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Keith W. Pratz, Douglas E. Gladstone, Margaret M. Showel, Megan Othus, L. Austin Doyle, James R. Wright, John M. Pagel	2012	49
16	High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas Leukemia & lymphoma ·Douglas E. Gladstone, Javier Bolaños‐Meade, Carol Ann Huff, Marianna Zahurak, Ian W. Flinn, Ivan Borrello, Leo Luznik, Ephraim J. Fuchs, Yvette L. Kasamon, William Matsui, Jonathan D. Powell, Hyam I. Levitsky, Robert A. Brodsky, Richard F. Ambinder, Richard J. Jones, Lode J. Swinnen	2011	4
17	Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia Leukemia & lymphoma ·Douglas E. Gladstone, Lode J. Swinnen, Yvette L. Kasamon, Amanda L. Blackford, Christopher D. Gocke, Constance A. Griffin, Sonneck Torben, Richard J. Jones	2011	12
18	High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients Journal of Neuroimmunology ·Douglas E. Gladstone, Marc G. Golightly, Thomas H. Brannagan	2007	24
19	Effective CD34+ stem cell mobilization with low-dose pegfilgrastim Journal of Applied Research ·Timothy S. Pardee, Nabil Hagag, Shuide Chen, Kenneth W. Zamkoff, مهنوش محمودی, Erik Karlkvist, Douglas E. Gladstone	2006	3
20	Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia Biology of Blood and Marrow Transplantation ·Douglas E. Gladstone, Atul Bedi, Carole B. Miller, Stephen J. Noga, Constance A. Griffin, Steven Piantadosi, Pablo J. Cagnoni, Robert A. Brodsky, Benjamin D. Smith, Хубаева, N A, 何宪民	1999	11

About Douglas E. Gladstone

Douglas E. Gladstone is a scholar working on Hematology, Genetics, Transplantation, Pathology and Forensic Medicine and Immunology, having authored 113 papers that have together received 2.5k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (36 papers), Chronic Lymphocytic Leukemia Research (29 papers), Lymphoma Diagnosis and Treatment (21 papers), Acute Myeloid Leukemia Research (13 papers), Acute Lymphoblastic Leukemia research (13 papers), Polyomavirus and related diseases (12 papers), T-cell and B-cell Immunology (10 papers) and Renal Transplantation Outcomes and Treatments (8 papers). The work is most often cited by research in Hematology (1.1k citations), Transplantation (154 citations), Genetics (437 citations), Immunology (680 citations) and Pathology and Forensic Medicine (529 citations). Douglas E. Gladstone has collaborated with scholars based in United States, Italy and Spain. Frequent co-authors include Richard J. Jones, Ephraim J. Fuchs, Lode J. Swinnen, Robert A. Brodsky, Richard F. Ambinder, Leo Luznik, Javier Bolaños‐Meade, Thomas H. Brannagan, Ivan Borrello and Richard I. Yeaton. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Blood Advances, Leukemia Research and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact